Document is current
Any future updates will be listed below
-
Authors
Strunk, Crawford
Campbell, Andrew
Colombatti, Raffaella
Andemariam, Biree
Kesse-Adu, Rachel
Treadwell, Marsha
Inusa, Baba P. D.
- License Information
-
More Information
Article History
Accepted: 13 November 2020
First Online: 16 December 2020
Ethics approval and consent to participate
: NA
: NA
: A Campbell: research funding and consultancy from Global Blood Therapeutics (GBT), Novartis; and consultancy for Bluebird Bio; B Andemariam: consultancy for Bluebird Bio, CRISPR/Vertex, Novartis, NovoNordisk, Roche, Cyclerion, Terumo, Sanofi; DSMB: Global Blood Therapeutics; research funding: Imara; B Inusa: education funding: Novartis, AstraZeneca, Global Blood Therapeutics, Celgene, Vertex; ARISE declaration: This project has received funding from the European Union Horizon 2020 Research and Innovation Programme under Marie-Sklowdowska Curie Agreement, No 824021 ARISE project C. Strunk: consultancy Global Blood Therapeutics, Novartis and Medunik USA and Forma Therapeutics; R Colombatti: research funding: Global Blood Therapeutics, Novartis. No disclosures to declare from the other co-authors.
